Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review
- PMID: 36229093
- DOI: 10.1016/j.jacc.2022.08.743
Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review
Abstract
The population of patients with cancer is rapidly expanding, and the diagnosis and monitoring of cardiovascular complications greatly rely on imaging. Numerous advances in the field of cardio-oncology and imaging have occurred in recent years. This review presents updated and practical approaches for multimodality cardiovascular imaging in the cardio-oncology patient and provides recommendations for imaging to detect the myriad of adverse cardiovascular effects associated with antineoplastic therapy, such as cardiomyopathy, atherosclerosis, vascular toxicity, myocarditis, valve disease, and cardiac masses. Uniquely, we address the role of cardiovascular imaging in patients with pre-existing cardiomyopathy, pregnant patients, long-term survivors, and populations with limited resources. We also address future avenues of investigation and opportunities for artificial intelligence applications in cardio-oncology imaging. This review provides a uniform practical approach to cardiovascular imaging for patients with cancer.
Keywords: cardio-oncology; imaging; multimodality.
Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures Dr Baldassarre has received research funding from the American Heart Association (18CDA34110361) and the National Center for Advancing Translational Science (NCATS), a component of the National Institute of Health (UL1 TR001863). Dr Yang has received research funding from CSL Behring, Boehringer Ingelheim, and Eli Lilly; and has received consultation fees from Pfizer. Dr Zaha is supported by the Cancer Prevention Research Institute of Texas (RP180404). Dr Dent has received research funding and honoraria from Novartis. Dr Deswal is supported in part by the Ting Tsung and Wei Fong Chao Distinguished Chair. Dr Liu has received research funding from Johnson and Johnson; has received consultation fees from Caption Health and Phillips; and has served on the DMSB for Caelum Biosciences. Dr Scherrer-Crosbie is supported by the National Heart, Lung, and Blood Institute (R01HL130539). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
